Allele-Skewed HLA-DR Immunopeptidomes of Bordetella pertussis
Background/Objectives: Infection with Bordetella pertussis causes whooping cough. CD4+ T cell responses depend on bacterial peptides displayed by HLA class II, yet allele- and strain-resolved maps of naturally processed B. pertussis HLA-DR ligands remain limited. We sought to define which antigens yield HLA-DR ligands in a human macrophage model and whether presentation is skewed by HLA-DR molecule and bacterial strain. Methods: THP-1–derived macrophages were pulsed with whole-cell lysates of B. pertussis vaccine/reference strain Tohama I or clinical isolate D420. HLA-DR was immunoaffinity purified; eluted peptides were identified by LC-MS/MS and assigned to HLA-DR molecules encoded by HLA-DRB1*01:01, HLA-DRB1*15:01, and HLA-DRB5*01:01. Results: We identified 63 B. pertussis peptide ligands from 29 source proteins. Presentation was skewed by HLA-DR molecule: DRB1*01:01 accounted for 37 ligands from 21 antigens, DRB1*15:01 for 22 from 7, and DRB5*01:01 for 4 from 4. Most source proteins contributed ligands primarily to one HLA-DR molecule, so an antigen that supplies peptides to one DR product need not supply peptides to another. Strain further partitioned the ligandome: 32 ligands unique to Tohama I, 12 to D420, and only 19 from 8 proteins with both lysates. Only three antigens contributed ligands to both DRB1*01:01 and DRB1*15:01; two of these, pertactin and filamentous hemagglutinin, are components of current acellular pertussis vaccines. Conclusions: B. pertussis HLA-DR ligandomes are jointly shaped by bacterial strain and HLA-DR molecule. Antigens can interact selectively with individual HLA-DR products, and peptides from a given antigen may be recovered after pulse with one strain but not another. These findings support HLA-DR and strain-aware interpretation of class II presentation and nominate BrkA autotransporter (Bordetella resistance to killing A), outer membrane protein A (OmpA), tracheal colonization factor (TcfA), and a divalent metal transporter (DMT) family transporter for follow-up.
Authors
- Saghar Kaabinejadian (ORCID: https://orcid.org/0000-0002-8434-8703)
- Alessandro Sette (ORCID: https://orcid.org/0000-0001-7013-2250)
- Hooman Yari (ORCID: https://orcid.org/0000-0002-8285-7985)
- Sandra K. Armstrong (ORCID: https://orcid.org/0000-0001-7648-6244)
- William H. Hildebrand (ORCID: https://orcid.org/0000-0002-7066-4174)
- Ricardo da Silva Antunes (ORCID: https://orcid.org/0000-0001-9785-5272)
- Timothy J. Brickman
Institutions
- La Jolla Institute for Immunology (US)
- University of California San Diego (US)
- University of Minnesota Medical Center (US)
- University of Oklahoma Health Sciences Center (US)
Publication Details
- Journal
- Vaccines
- Published
- 2026-08-25
- DOI
- https://doi.org/10.3390/vaccines14090733
- Primary Topic
- Bacterial Infections and Vaccines
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Institute of Allergy and Infectious Diseases